Published in Nat Med on October 11, 2011
Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog (2012) 1.74
A mouse model for HIV-1 entry. Proc Natl Acad Sci U S A (2012) 1.23
A global approach to HIV-1 vaccine development. Immunol Rev (2013) 1.14
HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection. Retrovirology (2012) 1.06
Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol (2014) 1.06
Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J Immunol (2014) 1.04
Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. J Virol (2014) 0.94
A "prime-pull" vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice. PLoS One (2013) 0.85
Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology (2014) 0.85
Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. J Immunol (2014) 0.84
Advances in antiviral vaccine development. Immunol Rev (2013) 0.82
Lessons learned from HIV vaccine clinical efficacy trials. Curr HIV Res (2013) 0.79
HIV-1 Env antibodies: are we in a bind or going blind? Nat Med (2012) 0.79
Predicting first traversal times for virions and nanoparticles in mucus with slowed diffusion. Biophys J (2015) 0.77
Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. J Virol (2014) 0.77
Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein. AIDS Res Hum Retroviruses (2015) 0.76
A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens. PLoS One (2015) 0.76
Modulation of SIV and HIV DNA vaccine immunity by Fas-FasL signaling. Viruses (2015) 0.75
Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection. AIDS Res Hum Retroviruses (2015) 0.75
Fcgbp - A Potential Viral Trap in RV144. Open AIDS J (2014) 0.75
HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost. PLoS One (2016) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (1992) 4.75
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science (2011) 4.13
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog (2011) 3.29
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine (2011) 1.91